These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22226101)

  • 1. Hematopoietic cell transplantation for nonmalignant disorders.
    Tolar J; Mehta PA; Walters MC
    Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S166-71. PubMed ID: 22226101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies.
    Chaudhri NA; Aljurf M; Almohareb FI; Alzahrani HA; Bashir Q; Savani B; Gupta V; Hashmi SK
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):173-177. PubMed ID: 28692818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.
    Thakar MS; Broglie L; Logan B; Artz A; Bunin N; Burroughs LM; Fretham C; Jacobsohn DA; Loren AW; Kurtzberg J; Martinez CA; Mineishi S; Nelson AS; Woolfrey A; Pasquini MC; Sorror ML
    Blood; 2019 Feb; 133(7):754-762. PubMed ID: 30545834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes.
    Li Q; Luo C; Luo C; Wang J; Li B; Ding L; Chen J
    Ann Hematol; 2017 Aug; 96(8):1389-1397. PubMed ID: 28623394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity conditioning (RIC) in children with nonmalignant disorders (NMD) undergoing unrelated donor umbilical cord blood transplantation (UCBT).
    Parikh S; Szabolcs P
    Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S53-5. PubMed ID: 22226113
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.
    Peffault de Latour R; Peters C; Gibson B; Strahm B; Lankester A; de Heredia CD; Longoni D; Fioredda F; Locatelli F; Yaniv I; Wachowiak J; Donadieu J; Lawitschka A; Bierings M; Wlodarski M; Corbacioglu S; Bonanomi S; Samarasinghe S; Leblanc T; Dufour C; Dalle JH; ;
    Bone Marrow Transplant; 2015 Sep; 50(9):1168-72. PubMed ID: 26052913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.
    Dietz AC; Mehta PA; Vlachos A; Savage SA; Bresters D; Tolar J; Boulad F; Dalle JH; Bonfim C; de la Fuente J; Duncan CN; Baker KS; Pulsipher MA; Lipton JM; Wagner JE; Alter BP
    Biol Blood Marrow Transplant; 2017 May; 23(5):726-735. PubMed ID: 28115275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
    Pantin J; Tian X; Shah AA; Kurlander R; Ramos C; Cook L; Khuu H; Stroncek D; Leitman S; Barrett J; Donohue T; Young NS; Geller N; Childs RW
    Am J Hematol; 2013 Oct; 88(10):874-82. PubMed ID: 23813900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group.
    Mohamed SY; Fadhil I; Hamladji RM; Hamidieh AA; Fahmy O; Ladeb S; Alimoghaddam K; Elhaddad A; Nacer RA; Alsharif F; Rasheed W; Jahani M; Mousavi SA; Alseraihy A; Abdel-Rahman F; Al Jefri A; Hussein AA; Alabdulaaly A; Ibrahim A; Bekadja MA; Abboud M; Ahmed P; Dennison D; Bakr M; Benchekroun S; Hussain F; Othman TB; Aljurf M; Ghavamzadeh A
    Hematol Oncol Stem Cell Ther; 2011; 4(2):81-93. PubMed ID: 21727769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT.
    Dietz AC; Savage SA; Vlachos A; Mehta PA; Bresters D; Tolar J; Bonfim C; Dalle JH; de la Fuente J; Skinner R; Boulad F; Duncan CN; Baker KS; Pulsipher MA; Lipton JM; Wagner JE; Alter BP
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1422-1428. PubMed ID: 28533057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
    Srinivasan R; Takahashi Y; McCoy JP; Espinoza-Delgado I; Dorrance C; Igarashi T; Lundqvist A; Barrett AJ; Young NS; Geller N; Childs RW
    Br J Haematol; 2006 May; 133(3):305-14. PubMed ID: 16643433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria.
    Lee JL; Lee JH; Lee JH; Choi SJ; Kim S; Seol M; Lee YS; Chi HS; Park CJ; Kim WK; Lee JS; Lee KH
    Eur J Haematol; 2003 Aug; 71(2):114-8. PubMed ID: 12890150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders.
    Bhatt ST; Bednarski JJ
    Front Immunol; 2020; 11():1988. PubMed ID: 33013851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Change in paradigm in the treatment of pediatric acquired bone marrow failure syndromes in Hungary].
    Kállay K; Csomor J; Ádám E; Bödör C; Kassa C; Simon R; Kovács G; Péter G; Ottóffy G; Bartyik K; Kiss C; Masát P; Réti M; Tóth B; Kriván G
    Orv Hetil; 2018 Oct; 159(42):1710-1719. PubMed ID: 30334483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia.
    Lee SE; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Lee JW
    Eur J Haematol; 2017 Oct; 99(4):336-343. PubMed ID: 28675769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children.
    Andolina JR; Reinish AL; Akhtar R; Noronha S; Shand JC; Girvin A; Korones DN; Bruckner LB; Mullen CA; Curran KJ; Boulad F
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27218. PubMed ID: 29722478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.
    Burroughs LM; Shimamura A; Talano JA; Domm JA; Baker KK; Delaney C; Frangoul H; Margolis DA; Baker KS; Nemecek ER; Geddis AE; Sandmaier BM; Deeg HJ; Storb R; Woolfrey AE
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1669-1677. PubMed ID: 28602958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
    Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
    Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.
    Passweg JR; Baldomero H; Basak GW; Chabannon C; Corbacioglu S; Duarte R; Kuball J; Lankester A; Montoto S; de Latour RP; Snowden JA; Styczynski J; Yakoub-Agha I; Arat M; Mohty M; Kröger N;
    Bone Marrow Transplant; 2019 Oct; 54(10):1575-1585. PubMed ID: 30728439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.